---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289204248.md"
description: "Cartesian Therapeutics shares are trading higher after announcing a strategic licensing agreement with WestGene to advance the development of in vivo chimeric antigen receptor T-cell therapies in autoimmune diseases."
datetime: "2026-06-09T14:02:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289204248.md)
  - [en](https://longbridge.com/en/news/289204248.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289204248.md)
---

# 

Cartesian Therapeutics shares are trading higher after announcing a strategic licensing agreement with WestGene to advance the development of in vivo chimeric antigen receptor T-cell therapies in autoimmune diseases.

### Related Stocks

- [RNAC.US](https://longbridge.com/en/quote/RNAC.US.md)

## Related News & Research

- [New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market](https://longbridge.com/en/news/289223615.md)
- [Does Zevra Therapeutics (ZVRA) Patent Push and Board Structure Signal a Shifting Risk Profile?](https://longbridge.com/en/news/289197310.md)
- [New Talvey Plus Darzalex Faspro Data Demonstrate The Strength Of A Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma](https://longbridge.com/en/news/289663072.md)
- [CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead](https://longbridge.com/en/news/289285000.md)
- [MBX Biosciences Highlights Sustained Calcium Control In Rare Disease](https://longbridge.com/en/news/289614050.md)